Conclusions
medulloblastoma, difficult-to-treat
MEDULLOBLASTOMA
This nonrandomized controlled trial found that the MEMMAT regimen is a feasible and promising strategy for patients who have previously received irradiation. Given this meaningful clinical benefit in a difficult-to-treat population, further evaluation of the combination is warranted. In the future, an improved understanding of the molecular signature and specific pathways of medulloblastoma groups and subgroups may allow us to add targeted therapies to a MEMMAT backbone.